SONAL MEHTA
Prescription History 1689137739
Internal Medicine - Endocrinology, Diabetes & Metabolism in New York, NY

NPI Status: Active since April 06, 2019

Contact Information

222 E 41ST ST FL 23
NEW YORK, NY
ZIP 10017
Phone: (212) 481-1350
Fax: (212) 481-1355

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SONAL MEHTA, an active Endocrinology, Diabetes & Metabolism specialist practicing in New York, NY. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 52 documented patient claims. Among these therapy options, the most frequently utilized medication is Levothyroxine Sodium, which accounts for 35 claims alone.

Medication Index

No matching medications currently found on file.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 35
30-Day Fills 91.0
Days Supply 2,701
NY State Average Benchmarks
Peer Average Claims129.0
Peer Average 30-Day Fills277.6
Peer Average Days Supply8,147
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $673.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.25

State Avg Cost Per Claim

$18.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Novolog Flexpen

Generic Formulation: Insulin AspartSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 17
30-Day Fills 31.3
Days Supply 860
NY State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills59.0
Peer Average Days Supply1,655
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.4% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,894.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,346.75

State Avg Cost Per Claim

$851.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.

Therapeutic Applications

Insulin aspart is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin aspart is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin aspart starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SONAL MEHTA provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Endocrinology, Diabetes & Metabolism** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.